- Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate
- The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concerns
- Tryp is preparing Phase 2a and Phase 2b clinical trials and expects to advance its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) platform in conjunction with research teams at the University of Florida and the University of Michigan
- The DEA recently recommended a significant increase in cannabis and psilocybin use in medical science research, and the White House has asked Congress to consider changing drug legislation to better address the use of those drugs in clinical research
Two years after the U.S. Food and Drug Administration (“FDA”) declared the hallucinogenic substance psilocybin a “breakthrough therapy” to speed the process of the drug’s scientific clinical trials and reviews (https://ibn.fm/umfbQ), Michigan continues to cement its reputation as a hotbed for medicinal psychedelics advocacy and research, and proponents there believe society has reached a watershed moment for the substances’ acceptance.
Law enforcement officials in the state’s Ann Arbor region have effectively decriminalized natural compounds with hallucinogenic properties deemed illegal under state and federal law (although not synthetic compounds such as LSD), and last month Ann Arbor’s City Council voted 10-0 to declare September “Entheogenic Plant and Fungi Awareness Month.” As a result, the city will celebrate a “sacred plant and mushroom festival” called Entheo Fest every September, beginning Sept. 19 (https://ibn.fm/1UXcX).
The decisions highlight a growing cultural shift not unlike the transformation of cannabis’ stigma to a general acceptance of marijuana’s potential for therapeutic and recreational use when produced under quality constraints by recognized business enterprises in recent years.
Earlier this month, the Drug Enforcement Administration (“DEA”) proposed a huge increase in the production of marijuana and psilocybin for research purposes with the hope of accelerating new federally approved therapeutic medications (https://ibn.fm/6t5FB). The White House then issued a set of recommendations to Congress asking lawmakers to consider addressing addiction worries and proposals for new clinical research involving marijuana and psychedelics by changing the way select hallucinogenic substances are regulated (https://ibn.fm/dWPuE).
San Diego-based Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on novel bioscience solutions for medical conditions with unmet needs, specifically oriented toward developing its synthetic psilocybin candidates through clinical trials that target chronic pain and select eating disorders.
The company expects to soon launch a Phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome (“PWS”), hypothalamic obesity eating disorder resulting from the removal of a brain tumor, and binge eating disorder. TRP-8802 will be used in combination with psychotherapy under professional care.
“Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders,” Dr. Jennifer Miller, the trial’s principal investigator, stated during an interview with The Dales Report in May (https://ibn.fm/7eX83).
“Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect,” the company added in a news release last month (https://ibn.fm/ljJmr). “Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming Phase 2a clinical trial for eating disorders”.
Tryp Therapeutics then plans to proceed into Phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain barrier and effectively respond to pain and addiction concerns.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.